JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME Activity
Right arrow An erratum has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Iagaru, A.
Right arrow Articles by McDougall, I. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Iagaru, A.
Right arrow Articles by McDougall, I. R.
Journal of Nuclear Medicine Vol. 48 No. 3 379-389
© 2007 by Society of Nuclear Medicine


Continuing Education

Treatment of Thyrotoxicosis*

Andrei Iagaru and I. Ross McDougall

Division of Nuclear Medicine and Molecular Imaging Program at Stanford, Department of Radiology, Stanford University Medical Center, Stanford, California

Correspondence: For correspondence or reprints contact: I. Ross McDougall, Department of Radiology, Stanford University Medical Center, 300 Pasteur Dr., Room H-0101, Stanford, CA 94305-5281. E-mail: ross.mcdougall{at}stanford.edu

In this review, the causes of thyrotoxicosis and the treatment of syndromes with increased trapping of iodine are discussed. The benefits and the potential side effects of 3 frequently used therapies—antithyroid medications, thyroidectomy, and 131I treatment—are presented. The different approaches to application of 131I treatment are described. Treatment with 131I has been found to be cost-effective, safe, and reliable.

Key Words: thyrotoxicosis • antithyroid medications • 131I treatment • thyroidectomy • Graves' disease • toxic nodular goiter

* NOTE: FOR CE CREDIT, YOU CAN ACCESS THIS ACTIVITY THROUGH THE SNM WEB SITE (http://www.snm.org/ce_online) THROUGH MARCH 2008.

COPYRIGHT © 2007 by the Society of Nuclear Medicine, Inc.


Related articles in JNM:

This Month in JNM

JNM 2007 48: 9a-10a. [Full Text]  



This article has been cited by other articles:


Home page
JNMHome page
E. S. Mittra, R. D. Niederkohr, C. Rodriguez, T. El-Maghraby, and I. R. McDougall
Uncommon Causes of Thyrotoxicosis
J. Nucl. Med., February 1, 2008; 49(2): 265 - 278.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. Dardano, M. Ballardin, M. Ferdeghini, E. Lazzeri, C. Traino, N. Caraccio, G. Mariani, R. Barale, and F. Monzani
Anticlastogenic Effect of Ginkgo Biloba Extract in Graves' Disease Patients Receiving Radioiodine Therapy
J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4286 - 4289.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
M. A. Walter, J. Muller-Brand, and B. Muller
Antithyroid Drugs and Radioiodine and the Absence of Evidence
J. Nucl. Med., August 1, 2007; 48(8): 1403a - 1403a.
[Full Text] [PDF]


Home page
JNMHome page
I. R. McDougall and A. Iagaru
Reply: Antithyroid Drugs and Radioiodine and the Absence of Evidence
J. Nucl. Med., August 1, 2007; 48(8): 1403b - 1404.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2007 by the Society of Nuclear Medicine.